174 related articles for article (PubMed ID: 37853962)
1. Circulating cell-free HPV DNA is a strong marker for disease severity in cervical cancer.
Bønløkke S; Steiniche T; Sorensen BS; Nyvang GB; Lindegaard JC; Blaakær J; Bertelsen J; Fuglsang K; Strube ML; Lenz S; Stougaard M
Mol Oncol; 2024 May; 18(5):1231-1244. PubMed ID: 37853962
[TBL] [Abstract][Full Text] [Related]
2. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients.
Bønløkke S; Stougaard M; Sorensen BS; Booth BB; Høgdall E; Nyvang GB; Lindegaard JC; Blaakær J; Bertelsen J; Fuglsang K; Strube ML; Lenz S; Steiniche T
Cells; 2022 Jul; 11(14):. PubMed ID: 35883612
[TBL] [Abstract][Full Text] [Related]
3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
4. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.
Galati L; Combes JD; Le Calvez-Kelm F; McKay-Chopin S; Forey N; Ratel M; McKay J; Waterboer T; Schroeder L; Clifford G; Tommasino M; Gheit T
Microbiol Spectr; 2022 Apr; 10(2):e0148021. PubMed ID: 35225653
[TBL] [Abstract][Full Text] [Related]
5. Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.
Guerrero-Preston R; Valle BL; Jedlicka A; Turaga N; Folawiyo O; Pirini F; Lawson F; Vergura A; Noordhuis M; Dziedzic A; Pérez G; Renehan M; Guerrero-Diaz C; De Jesus Rodríguez E; Diaz-Montes T; Rodríguez Orengo J; Méndez K; Romaguera J; Trock BJ; Florea L; Sidransky D
Cancer Prev Res (Phila); 2016 Dec; 9(12):915-924. PubMed ID: 27671338
[TBL] [Abstract][Full Text] [Related]
6. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma.
Guo M; Sneige N; Silva EG; Jan YJ; Cogdell DE; Lin E; Luthra R; Zhang W
Mod Pathol; 2007 Feb; 20(2):256-66. PubMed ID: 17192787
[TBL] [Abstract][Full Text] [Related]
7. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
8. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas.
Liu SS; Tsang PC; Chan KY; Cheung AN; Chan KK; Leung RC; Ngan HY
Tumour Biol; 2008; 29(2):105-13. PubMed ID: 18515988
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy of HPV DNA in cervical cancer.
Cheung TH; Yim SF; Yu MY; Worley MJ; Fiascone SJ; Chiu RWK; Lo KWK; Siu NSS; Wong MCS; Yeung ACM; Wong RRY; Chen ZG; Elias KM; Chung TKH; Berkowitz RS; Wong YF; Chan PKS
J Clin Virol; 2019 May; 114():32-36. PubMed ID: 30913520
[TBL] [Abstract][Full Text] [Related]
10. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma.
Saunier M; Monnier-Benoit S; Mauny F; Dalstein V; Briolat J; Riethmuller D; Kantelip B; Schwarz E; Mougin C; Prétet JL
J Clin Microbiol; 2008 Nov; 46(11):3678-85. PubMed ID: 18799702
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
12. Targeted next generation sequencing panel for HPV genotyping in cervical cancer.
Lippert J; Bønløkke S; Utke A; Knudsen BR; Sorensen BS; Steiniche T; Stougaard M
Exp Mol Pathol; 2021 Feb; 118():104568. PubMed ID: 33171155
[TBL] [Abstract][Full Text] [Related]
13. Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients.
Patel DA; Unger ER; Walline H; Opipari AW; Lee DR; Flowers LC; Ruffin MT
J Clin Virol; 2011 Apr; 50(4):342-4. PubMed ID: 21306941
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus multiplex ligation-dependent probe amplification assay for the assessment of viral load, integration, and gain of telomerase-related genes in cervical malignancies.
Theelen W; Litjens RJ; Vinokurova S; Haesevoets A; Reijans M; Simons G; Smedts F; Herrington CS; Ramaekers FC; von Knebel Doeberitz M; Speel EJ; Hopman AH
Hum Pathol; 2013 Nov; 44(11):2410-8. PubMed ID: 23968641
[TBL] [Abstract][Full Text] [Related]
15. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
16. Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer.
Thangarajah F; Busshoff J; Salamon J; Pruss MS; Lenz C; Morgenstern B; Hellmich M; Schlößer HA; Lenz M; Domröse C; Mallmann MR; Mallmann P; Weiß J; Franzen F; Merkelbach-Bruse S; Binot E; Eich ML; Büttner R; Schultheis AM; Alidousty C
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12597-12604. PubMed ID: 37452202
[TBL] [Abstract][Full Text] [Related]
17. High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities.
Norman I; Hjerpe A; Andersson S
Oncol Rep; 2013 Aug; 30(2):695-700. PubMed ID: 23756570
[TBL] [Abstract][Full Text] [Related]
18. Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker.
Rungkamoltip P; Temisak S; Piboonprai K; Japrung D; Thangsunan P; Chanpanitkitchot S; Chaowawanit W; Chandeying N; Tangjitgamol S; Iempridee T
Exp Biol Med (Maywood); 2021 Mar; 246(6):654-666. PubMed ID: 33307803
[TBL] [Abstract][Full Text] [Related]
19. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
[TBL] [Abstract][Full Text] [Related]
20. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Jeannot E; Latouche A; Bonneau C; Calméjane MA; Beaufort C; Ruigrok-Ritstier K; Bataillon G; Larbi Chérif L; Dupain C; Lecerf C; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Jordanova ES; von der Leyen H; Tran-Perennou C; Legrier ME; Dureau S; Raizonville L; Bello Roufai D; Le Tourneau C; Bièche I; Rouzier R; Berns EMJJ; Kamal M; Scholl S
Clin Cancer Res; 2021 Nov; 27(21):5869-5877. PubMed ID: 34210686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
